Composition with non-digestible oligosaccharides for attenuating nasal epithelial inflammation
a technology of oligosaccharides and epithelial inflammation, which is applied in the direction of drug compositions, immunological disorders, dispersed delivery, etc., can solve the problems of nasal dripping or “runny”, excessive mucus production, and rhinitis symptoms, so as to reduce the secretion of pro-inflammatory chemokines and improve the effect of anti-inflammatory effects and anti-inflammatory effects
Inactive Publication Date: 2019-12-26
VAN BERGENHENEGOUWEN JEROEN +3
View PDF2 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The patent is about the discovery of non-digestible oligosaccharides that can help decrease the inflammation and allergic response in human nasal epithelial cells. These oligosaccharides can be beneficial in preventing and treating non-allergic rhinitis, a common respiratory illness in infants and young children. The patent is directed to compositions containing these particular oligosaccharides.
Problems solved by technology
This inflammation results in the production of excessive amounts of mucus, resulting in the primary symptom of rhinitis, nasal dripping or “runny nose”, as well as nasal congestion, rhinoconjunctivitis (inflammation of conjunctiva) and post-nasal drip.
It has a considerable negative impact on the quality of life of both the parent and child.
Infants with blocked noses struggle to breathe while being milk-fed, and young children are unable to blow their noses properly to ease their discomfort.
Infants and children with a blocked nose have difficulty sleeping at night too.
Furthermore, young infants are not able to mouth breath properly and can only do so by crying.
Rhinitis in infants and children has been associated with sleeping problems, ear conditions, and even learning problems.
However, the effect of non-digestible oligosaccharides is not tested.
However, the effect of non-digestible oligosaccharides is not tested.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example 1
f Prebiotics and Probiotics on IFN-γ / TNF-α Stimulated Nasal Epithelial Cells
[0046]Since long the use of human nasal epithelial cells has been known as a suitable in vitro model system, see for example Schmidt et al., Advanced Drug Delivery Reviews, 1998, 29:51-79. Human primary nasal epithelial cells (HNECs) were isolated from non-atopic (NA) subjects, grown and frozen in liquid nitrogen for further use. To exert the experiments in monolayer, human primary epithelial cells (HNECs) were thawed and seeded in Airway Epithelial Cell Growth Medium (AEGM) with supplements (PromoCell, C-21060) in 24 wells plates. The cells were incubated at 37° C. at 5 CO2 for 5-6 days until they reached 80% confluence. On the morning of the experiment the mixture short chain galacto-oligosaccharides / long chain fructo-oligosaccharides (scGOS / IcFOS) was freshly prepared. Moreover probiotic bacteria, Lactobacillus rhamnosus LW744 and cytokines were thawed and diluted to the working concentration. scGOS / IcFOS...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| Time | aaaaa | aaaaa |
| Composition | aaaaa | aaaaa |
| Digestibility | aaaaa | aaaaa |
Login to View More
Abstract
The present invention relates to the use of non-digestible oligosaccharides for the direct attenuation of nasal epithelial inflammation, in particular for non-allergic rhinitis, in particular for use in infants.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a bypass continuation of International Application No. PCT / EP2018 / 055708 filed Mar. 8, 2018, which claims priority to European Application No. 17159857.6 filed Mar. 8, 2017, the contents of which are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The invention relates to the use of non-digestible oligosaccharides for nasal inflammation.BACKGROUND OF THE INVENTION[0003]Rhinitis is generally considered to be chronic or acute inflammation of the mucous membrane of the nose. This inflammation results in the production of excessive amounts of mucus, resulting in the primary symptom of rhinitis, nasal dripping or “runny nose”, as well as nasal congestion, rhinoconjunctivitis (inflammation of conjunctiva) and post-nasal drip.[0004]Rhinitis is commonly categorised into three types: infectious rhinitis, including acute and chronic bacterial or viral infections; allergic rhinitis, commonly ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/702A61K9/00A61P11/02
CPCA61K9/0095A61K31/702A61P11/02A61K9/0043A61K31/733A23V2002/00A23L33/40A23L33/125A61K47/26A61K2300/00A23V2200/304A23V2250/284A23L29/30A61P31/16A61P37/00
Inventor VAN BERGENHENEGOUWEN, JEROENGARSSEN, JOHANTRAIDL-HOFFMANN, CLAUDIASCHLUMPRECHT, CAROLINE
Owner VAN BERGENHENEGOUWEN JEROEN